Allergan puts Vraylar on blockbuster track with new bipolar depression nod

Allergan, badly in need of good news, finally has some to share. On Tuesday, the FDA greenlighted the company’s Vraylar to treat bipolar depression, a key piece of its bid for billion-dollar sales.